Valuation: LTR Pharma Limited

Market Cap 99.07M 68.74M 60.29M 55.84M 51.38M 97.18M 6.58B 666M 261M 3.23B 258M 252M 11.16B P/E 2024
-15.6x
P/E 2025 -8.67x
Enterprise Value 67.26M 46.67M 40.93M 37.91M 34.88M 65.98M 4.47B 452M 177M 2.19B 175M 171M 7.57B EV / Sales 2024
2,155,942,064x
EV / Sales 2025 13,706,564x
Free-Float
58%
Yield 2024 *
-
Yield 2025 -
1 day-2.00%
1 week-10.09%
Current month-10.09%
1 month-5.77%
3 months+22.50%
6 months-17.65%
Current year-31.94%
1 week 0.48
Extreme 0.48
0.57
1 month 0.46
Extreme 0.465
0.64
Current year 0.35
Extreme 0.35
0.75
1 year 0.29
Extreme 0.29
0.81
3 years 0.24
Extreme 0.235
2.15
5 years 0.24
Extreme 0.235
2.15
10 years 0.24
Extreme 0.235
2.15
Manager TitleAgeSince
Investor Relations Contact - 30/09/2020
Director of Finance/CFO - -
Chief Tech/Sci/R&D Officer - -
Director TitleAgeSince
Director/Board Member - 05/09/2021
Chairman - 30/09/2020
Director/Board Member - -
Date Insider Type Main position Quantity % Market Cap.
11-19Free

Founder

2,000,000 1.1012%
11-19Free

Director

1,000,000 0.5506%
11-19Free

Director

1,000,000 0.5506%
Change 5-day change 1-year change 3-year change Capi.($)
-2.00%-10.09%+68.97% - 63.06M
-2.48%-2.22%+55.85%+79.12% 53.54B
-0.26%-6.72%+55.44%+126.83% 54.18B
-5.60%-2.15%+11.16%+420.46% 23.66B
-1.55%-4.11%-20.21%-17.75% 22.78B
+2.47%+4.51%+43.70%-6.01% 19.54B
-0.80%-0.18%+37.97%-27.89% 17.82B
-2.72%-4.04%+187.08%+362.09% 16.01B
-0.30%-2.33%+46.44%+660.61% 15.37B
-0.81%+0.92%+24.92%+189.61% 14.09B
Average -1.36%-2.82%+51.13%+198.56% 23.7B
Weighted average by Cap. -1.40%-2.00%+48.06%+163.12%

Financials

2024 2025
Net sales 0.05 0.03 0.03 0.03 0.03 0.05 3.25 0.33 0.13 1.6 0.13 0.12 5.52 1.51 1.05 0.92 0.85 0.78 1.48 100.17 10.13 3.97 49.19 3.93 3.84 169.88
Net income -6.95M -4.83M -4.23M -3.92M -3.61M -6.82M -462M -46.72M -18.32M -227M -18.12M -17.72M -783M -5.59M -3.88M -3.4M -3.15M -2.9M -5.49M -371M -37.58M -14.74M -182M -14.57M -14.25M -630M
Net Debt -3.1M -2.15M -1.89M -1.75M -1.61M -3.04M -206M -20.84M -8.17M -101M -8.08M -7.91M -349M -31.81M -22.07M -19.36M -17.93M -16.5M -31.2M -2.11B -214M -83.81M -1.04B -82.87M -81.06M -3.58B
Logo LTR Pharma Limited
LTR Pharma Limited is an Australia-based clinical-stage biopharmaceutical company. The Company is developing and commercializing therapies that address significant unmet medical needs. The Company is focused on improving men’s health through clinical development and commercialization of nasal spray treatments for erectile dysfunction. Its lead products, SPONTAN and ROXUS, are fast-acting intranasal sprays for the treatment of erectile dysfunction, enabling onset of action in 10 minutes or less. The Company is also advancing OROFLOW, a novel intranasal spray under development for the treatment of Oesophageal Motility Disorders (OMD) - a debilitating group of conditions affecting swallowing function. The Company's subsidiary is LTR Pharma Inc.
Employees
-
Date Price Change Volume
14/07/26 A$0.4900 -2.00% 175,703
13/07/26 A$0.5000 -3.85% 91,385
10/07/26 A$0.5200 +4.00% 149,606
09/07/26 A$0.5000 -12.28% 306,821
08/07/26 A$0.5700 +4.59% 96,752